Physician profile
Fadi A Al-Khayer
NPI 1861477069
$488,988.96
in general payments reported to CMS, 2019-2025
19 companies · $90K in 2025
The $90K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $34K · 2021: $44K · 2022: $80K · 2023: $99K · 2024: $89K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Travel and Lodging: $22K · Honoraria: $19K · Food and Beverage: $8,797 · Consulting Fee: $4,280 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $222,887.25 |
| Travel and Lodging | $22,076.67 |
| Honoraria | $19,200.00 |
| Food and Beverage | $8,796.61 |
| Consulting Fee | $4,280.00 |
| Education | $107.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $144,476.10 | 2020-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $142,707.87 | 2020-2025 | Korlym |
| Novo Nordisk INC | $124,403.38 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $55,821.82 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $15,690.34 | 2019-2020 | |
| Abbvie INC. | $5,136.97 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $332.12 | 2024-2025 | Recorlev |
| Kyowa Kirin, INC. | $124.99 | 2023 | Crysvita |
| Amgen INC. | $58.27 | 2024-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $34.34 | 2021-2023 | Freestyle Libre 3 |
| Lexicon Pharmaceuticals, INC. | $28.96 | 2024 | |
| Insulet Corporation | $27.48 | 2025 | Omnipod |
| Almatica Pharma LLC | $26.12 | 2025 | Teriparatide |
| Senseonics, Incorporated | $23.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.46 | 2024 | Strensiq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.92 | 2025 | Xifaxan |
| Intra-Sana Laboratories | $20.84 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Recordati_rare_diseases_inc. | $17.24 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $16.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Al-Khayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.